InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

August 21, 2024

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

August 20, 2024

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

July 30, 2024

InMed to Present at the Emerging Growth Conference

June 10, 2024

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

April 18, 2024

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

April 16, 2024

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

April 4, 2024

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

March 20, 2024

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

February 13, 2024

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

February 9, 2024

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

January 18, 2024

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

January 16, 2024

InMed Announces Results of 2023 Annual General Meeting

December 19, 2023

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

November 29, 2023

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 14, 2023

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

November 2, 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 26, 2023

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 24, 2023

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 24, 2023

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals